Melasma-like hyperpigmentation: A rare side effect of imatinib mesylate
Imatinib mesylate is an oral tyrosine kinase inhibitor used chiefly to treat chronic myeloid leukemia. In the literature, hypopigmentation is a commonly reported side effect of imatinib therapy; however, the cases of melasma-like hyperpigmentation due to imatinib have also been sparingly reported. W...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Rangatū: | Journal of the Scientific Society |
| Ngā marau: | |
| Urunga tuihono: | http://www.jscisociety.com/article.asp?issn=0974-5009;year=2023;volume=50;issue=2;spage=275;epage=277;aulast=Agrawal |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|